Introduction: A number of strategies have been attempted to minimize the risk of infection following transrectal prostate procedures. We report our prospective efforts at augmenting our prophylaxis strategy over time.
Abbreviations and Acronyms
Transrectal ultrasound guided prostate biopsy is the standard of care for pathological diagnosis of prostate cancer and is performed more than 1 million times a year in the United States. 1, 2 Additionally, TRUS guided placement of fiducial markers is common practice in aiding image guided radiotherapy. While transrectal procedures of the prostate are generally safe, there are complications associated with the procedure including pain, hematuria, hematospermia, hematochezia, urinary tract infection and the most serious complication of sepsis. 3e7 The usefulness of antibiotic prophylaxis in minimizing infection is well established. However, there is no consensus that one particular class of antibiotics is superior. 8 The American Urological Association best practice policy statement recommends less than 24 hours of oral fluoroquinolone or intravenous 1st, 2nd or 3rd generation cephalosporin as first line coverage, and oral trimethoprim-sulfamethoxazole or IV aminoglycoside vs aztreonam as an alternative regimen. 9 However, there is considerable practice variation among U.S. urologists. 10 Since these recommendations were published in 2008, a number of reports indicate a rising incidence of infectious complications, in particular due to FQ resistance. 3, 11, 12 We describe our institutional experiences with infectious complications following TRPXs and attempts to combat this trend. This process involves fastidious prospective monitoring of complications and changes to our antibiotic prophylaxis regimen, first with the addition of IM aminoglycoside to our empiric regimen of oral FQ or TMP-SMX, and then with the addition of formalin disinfection of the biopsy needle between core sampling and rectal swab culture screening in high risk patients.
Materials and Methods

Study Overview and Antibiotic Prophylaxis Protocols
After identifying a high number of post-TRPX infections in 2010, we embarked on a strategy to optimize outcomes and prospectively collect complication data ( fig. 1) . 13 Before 7,15e17 Providers were given a form by our institution which identified criteria for rectal swab culture, and instructions on how to perform the test and order it in our electronic medical record. These patients were evaluated 2 weeks before the procedure with a digital rectal examination followed by a cotton swab inserted into the rectum and rotated gently along the anterior rectal wall. The swab was screened for FQ resistance. If identified, further sensitivities and organism identification were performed to aid in selecting targeted antibiotic prophylaxis.
Outcomes
The primary outcome for this study was the rate of hospitalization due to post-TRPX infectious complications. Secondary outcomes included urine and blood culture results and antibiotic susceptibilities. In addition, the results of rectal swab culture screening in high risk patients were examined to determine the incidence of FQ resistance in this subgroup.
Transrectal Prostate Procedures
All procedures were performed in the outpatient setting.
Patients were instructed to self-administer a sodium phosphate enema on the morning of the procedure. A dipstick urinalysis was obtained before the procedure, and patients with suspected UTI underwent urine microscopy and urine culture before the procedure. TRUS guided prostate biopsies were typically performed using a 12-core standard template or using magnetic resonance imaging fusion. Transrectal fiducial marker placement was performed under ultrasound guidance at right base, right apex and left mid gland. As previously described, starting in 2015 we instituted a process of formalin needle tip disinfection between biopsies.
Complication Identification
In 2010 we began a systematic process of following up with patients 1 week after their procedure to identify infectious complications, including those that resulted in admission to an outside facility. All patients were instructed to notify their physicians with fever or suspicion of infection. Additionally, each patient was contacted at the time of pathology review and asked about infectious complications. A 1-week interval was chosen to identify infections attributable to the TRPX as most post-TRPX infections will occur by this point.
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According to the Centers for Disease Control and Prevention a febrile UTI was defined as fever 38C (100.4F) or greater accompanied by lower urinary tract symptoms (ie urgency, frequency, dysuria or suprapubic tenderness), with or without a positive urine culture. Patients with these symptoms in addition to other signs indicating a systemic inflammatory response syndrome along with laboratory markers of systemic infection were hospitalized for suspected septicemia. 19 On admission for infection all patients had urine culture via clean-catch voided or catheterized specimen and blood cultures from 2 separate venipuncture sites.
Statistical Analysis
Patient demographics, clinical characteristics and Charlson comorbidity index are reported. 20 Rates of infection related hospitalizations are compared across the different protocols using chi-square analysis. Analysis was performed using SPSSÒ version 22.0 and statistical significance was defined by p <0.05.
Results
Infection Related Hospitalizations
From the beginning of 2010 through the first half of 2016 we performed 2,398 TRPXs and identified 41 patients (1.7%) who required hospitalization for infection after the procedure, including 34 after prostate biopsy and 7 following fiducial marker placement. Figure 2 depicts the infection related hospitalization rates during the study period. Eleven cases (3.8%) of infection related hospitalization occurred out of 290 TRPXs performed during the original phase of the study period (protocol 1). After initiating protocol 2 (addition of IM aminoglycoside) the infection related hospitalization rate decreased to 1.5% (21 patients out of 1,376 TRPXs, p¼0.01). In the first 3 years of protocol 2 (2011 to 2013) the infection related hospitalization rate was 1.1%, representing a 69% decrease in infectious complications (p <0.01). In the last year of protocol 2 (2014) the infection rate increased to 2.6%, representing a 149% increase over the previous 3 years on the same protocol (p¼0.03). After initiating protocol 3 (targeted prophylaxis and formalin needle tip disinfection) in 2015 to 2016 the infectious complication rate dropped to 1.2% (9 patients of 732 TRPXs), representing a 53% decrease in the infection rate compared to the prior year (p¼0.08).
For the 41 patients who were hospitalized for infection, mean AE SD age was 65.41 AE 7.98 years, mean serum prostate specific antigen level was 6.6 AE 3.0 ng/dl and mean prostate volume was 50.2 AE 25.3 cc. Mean Charlson comorbidity index with age was 2.6 AE 1.4. Five patients (12.2%) had a history of UTI, 4 (9.3%) had a history of prostatitis and 13 (31.7%) had a history of lower urinary tract symptoms. Other comorbidities included diabetes (10, 24.4%) and immunosuppression (1, 2.4%). Previous biopsy had been performed on 20 patients (48.8%) and mean number of cores taken was 12.7 AE 1.5.
The mean time to symptom onset after the procedure was 2.2 AE 2.1 days and mean hospitalization length was 4.2 AE 1.4 days. Patients presented with the symptoms of fever (85.4%), chills (71.8%), malaise (39.5%), dysuria (29.7%), urinary retention (13.5%) and urosepsis (26.3%). No patients required intensive care or died.
Microbiology Results
Of the 36 patients with full records available 27 (75.0%) had a specific organism isolated during evaluation (see table) . Bacteriuria was present in 25 patients (69.4%) and bacteremia was present in 12 patients (33.3%). Urine culture showed 10 patients (27.8%) with a negative result despite fever or other symptoms consistent with UTI. In 23 patients (63.9%) Escherichia coli was isolated, and there were 2 patients (5.6%) with Enterococcus faecalis, 1 (2.8%) with Pseudomonas aeruginosa and 1 (2.8%) with Bacteroides fragilis isolated after infectious evaluation.
Susceptibility of organisms isolated demonstrated no cases of in vitro resistance to carbapenems, piperacillin-tazobactam or monobactams. Resistance to FQs and TMP-SMX was found in 75% and 81.8% of isolates, respectively. Isolates were resistant to FQs and TMP-SMX 48.1% of the time. Sensitivity to 3rd and 4th generation cephalosporins was generally high (greater than 80%). Sensitivity to aminoglycosides was 75% before the initiation of IM aminoglycoside (protocol 1) and remained similar at 73.3% after the addition of IM aminoglycoside (protocol 2). We did not note any significant differences in the antibiotic susceptibility profiles of bacteria isolated during protocols 1 and 2.
Under protocol 3 we identified 84 patients (11.5%) out of a total of 732 TRPXs as being at high risk for harboring FQ resistant rectal flora. Of those patients screened 25 (29.8%) were identified as harboring FQ resistance. Infections developed in 4 patients despite their being identified as high risk and given targeted prophylaxis. In 2 patients no bacteria were isolated during evaluation, 1 had targeted prophylaxis after rectal swab culture revealed resistant E. coli but E. faecalis bacteremia subsequently developed, and in 1 culture data were not available as the patient presented to an outside facility.
Discussion
Our experience represents an attempt to stay ahead of the infection curve during transrectal prostate procedures. After noting an unacceptably high infection related hospitalization rate in 2010 of 3.8%, we instituted a policy of adding IM No. bacteria isolated aminoglycoside to our standard prophylaxis regimen, resulting in a significant decrease in infectious complications (0.7%) in 2011. We previously reported on the effectiveness of this strategy and in the first 3 years of instituting this prophylaxis regimen the infection related hospitalization rate remained low (1.1%). 13 However, in 2014 we noted a significant increase in complications (2.6%), prompting a reevaluation of our regimen. We identified reports purporting the benefits of targeted prophylaxis in high risk patients as most promising and logical. Additionally, we noted the report on the potential utility of formalin needle tip disinfection between prostate biopsies. 14 Starting in 2015 we added these strategies to our prophylaxis regimen and saw another decline in infectious complications (1.2%). Although empiric antibiotic prophylaxis has proven efficacy in decreasing the risk of infection after TRPX, increasing bacterial resistance patterns are resulting in a rise in infectious complications. 3, 6, 8, 12 Several strategies have been used to mitigate this risk. The addition of IM aminoglycoside to empiric prophylaxis has been reported as effective in a number of studies. 21, 22 However, other studies have failed to demonstrate a reduction in infectious complications. 23 Recently Miyazaki et al reported on a prospective randomized study comparing oral FQ alone vs oral FQ plus intravenous amikacin and they found no difference in febrile UTIs between the groups. 24 However, they were underpowered to detect a difference. Interestingly, the majority of bacteria isolated after IM aminoglycoside administration demonstrated in vitro susceptibility to aminoglycosides. This is not to say that the addition of IM aminoglycosides was not helpful, as we do not know how many patients would have experienced infections without it. However, it raises questions about the pharmacokinetics of this method of drug delivery, dosing and prostatic tissue penetration.
Issa et al described a technique of disinfecting the tip of the biopsy needle with formalin before prostate biopsy. 14 While they found no statistically significant difference in rates of infectious complications before (0.8%) and after adopting the technique (0.3%, p¼0.13), they did demonstrate ex vivo experiments that showed a lack of growth of FQ resistant E. coli after inoculation with the formalin disinfected needle. Although there is a lack of data on the longterm side effects (eg prostatitis) that could result from placing formalin on a biopsy needle, we considered this a simple, cost-effective method that might minimize the risk of infection and incorporated it into our practice in 2015.
Empiric prophylaxis is inherently problematic given the rising incidence of antibiotic resistance. There is geographic and temporal variation in resistance patterns, so one institution's empiric prophylaxis regimen may have little relevance to the local antibiogram of another. 25 Cussans et al performed a meta-analysis of 9 studies and found an overall FQ resistance rate of 22.8%. 26 The infection rates were significantly lower in the group that received targeted antibiotics (2.2%) compared to those that received empiric FQ (4.6%). Although we believed screening high risk patients for antibiotic resistance was effective, this strategy depends on properly identifying high risk patients. 7,15e17 However, 5 of the 9 patients in whom infectious complications developed during protocol 3 were not screened for FQ resistance. Increasing antibiotic resistance patterns will likely further complicate matters, requiring periodic reevaluation of screening criteria. Furthermore, rectal swab culture is not foolproof. Infectious complications developed in 4 patients in our cohort despite screening and targeted therapy. Of these patients no organism was identified in 3 but in 1 patient E. faecalis was isolated from serum after rectal swab identified resistant E. coli, demonstrating discordance between an isolate from rectal culture (which hosts multiple bacteria strains) and the pathogenic bacteria. Further complicating matters and perhaps explaining the negative evaluation in some cases is the possibility of colonization from fastidious organisms, including anaerobic bacteria.
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This finding warrants further examination. The cost of a rectal swab screen for FQ resistance was $35.00 and when identified, the cost of a reflex culture and organism identification was $55.31. Assuming a 10% to 20% rate of FQ resistance in our patient population, 28 expansion of screening to all patients would cost an average of $40.53 to $46.06 per patient. Based on our screening of only high risk patients, we screened 11.5% of patients and the incidence of FQ resistance in that population was 29.8%. Thus, the cost of instituting such a policy averaged out to $5.92 per patient.
Strengths of the study include the large sample size and prospective evaluation of infectious complications, including those that resulted in care at an outside facility. Limitations of the study are those inherent in nonrandomized analysis of a low event rate outcome. Additionally, some infectious complications may have occurred later than 1 week and would not have been captured in our analysis. We note that our initial prophylaxis regimen consisted of 3 days of antibiotics, a commonly used regimen, although a departure from American Urological Association best practice policy statement recommendation of less than 24 hours of treatment. 9 Based on a meta-analysis a longer course of antibiotics has been reported to decrease the risk of bacteriuria, and rates of other infectious complications favored a longer course despite not reaching statistical significance, possibly due underpowering. 8 The potential benefit of this strategy should be weighed against the recent U.S. Food and Drug Administration black box warning against FQs. 29 Additionally, we added 2 modifications to our prophylaxis regimen in protocol 3. Although this practice change was made to improve patient care based on best available data, this change makes it impossible to determine the impact of each modification separately.
Conclusions
While empiric prophylaxis is effective for most patients, documented uptrends in infection rates and significant geographic variations in antibiotic resistance patterns suggest that this strategy is suboptimal for high risk patients. Identifying these high risk patients, performing rectal culture screening and offering these patients targeted prophylaxis can result in a significant decrease in infectious complications. Quality control measures adjusted through fastidious real-time monitoring can lead to care improvement. 
Editorial Commentaries
Improving the safety of prostate biopsy is one way to reduce harms of prostate cancer detection and active surveillance, thereby improving the risk-benefit ratio of detection. Infection occurs in only 0.1% to 7% of patients. 1 However, sepsis develops in 0.3% to 3.1% of patients, and 0.5% to 1.9% are hospitalized within 30 days of biopsy, most due to infection, indicating that some of these infections are severe. 1,2 Thus, quality improvement efforts to monitor and reduce infection rates are extremely important. Such efforts must be balanced with antibiotic stewardship in order to limit antibiotic exposure for individuals and limit resistance in populations. Antibiotic resistance develops rapidly, and so monitoring infection rates, studying the pathogens and sensitivities, and adjusting the regimen become an iterative process.
The authors should be commended for espousing a pragmatic "all of the above" approach. They adjusted their standard regimen in response to a higher infection rate, instituted a practice of dipping the needle in formalin and used rectal swab cultures to personalize the regimen in patients at higher risk. As a result, their infection rate decreased from 3.79% to a respectable 1.23%.
The authors acknowledge that 24 hours of "the right" coverage is sufficient to reduce the risk of infection. Longer length of administration adds to the individual's exposure to antibiotic related side effects and contributes to antibiotic resistance in the community. Hospital epidemiologists, hospital antibiograms and published guidelines are excellent resources for selecting a standard regimen. However, the moving target of antibiotic resistance requires constant vigilance, and makes this an opportunity to learn and teach quality improvement methods.
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Transrectal ultrasound guided prostate biopsy is associated with significant infections, including sepsis, in approximately 1% of patients. The authors are to be commended for their careful monitoring and protocol adjustments in an effort to reduce their serious infection rate after transrectal ultrasound guided prostate biopsy. The initial decrease in infection related hospitalizations from 3.8% to 1.1% was associated with the addition of empiric IM aminoglycosides. However, increasing bacterial resistance subsequently rendered this approach less effective. The authors then added targeted prophylaxis for high risk patients (11% of their population). The fact that 5 of the 9 patients with infectious complications were not judged to be high risk indicates the limitation of this approach. They screened for fluoroquinolone resistance with plates containing 10 mg/ml ciprofloxacin. The concentration of ciprofloxacin in prostate tissue following administration of a single dose of 1,000 mg ciprofloxacin is approximately 4 to 5 mg/gm prostate tissue. 1 Thus, bacteria that are judged susceptible in vitro to greater than 5 mg ciprofloxacin are actually resistant to the 5 mg or less achievable in vivo. A more physiological approach would be to use 1 mg/ml ciprofloxacin in the screening for fluoroquinolone resistance. 2 Site specific monitoring for FQ resistance and real-time adjustments based on evidence provide measurable advantages to empiric prophylaxis, and should be an integral part of efforts to reduce infectious complications of transrectal ultrasound guided prostate biopsy.
